Trials / Completed
CompletedNCT01242670
Ross River Virus (RRV) Vaccine Study
A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,968 (actual)
- Sponsor
- Alachua Government Services, Inc. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to verify the safety and adequacy of the immune response produced by a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine and to demonstrate the consistency of manufacture of 3 separate lots of RRV vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ross River Virus Vaccine | Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2010-11-17
- Last updated
- 2015-10-09
Locations
17 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT01242670. Inclusion in this directory is not an endorsement.